Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

OUR FOCUS ON NEUROSCIENCE

We all know someone who has been affected by a neurological condition, like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, or rare diseases like spinal muscular atrophy, Huntington’s disease or ALS. There are hundreds of these disorders impacting nearly 100 million Americans alone.

These conditions can alter the very essence of what makes us human—the way we think, communicate, move and remember. Over time, they can slowly take away the unique qualities that make us who we are, or who we may one day become.

Our hope is to create a tomorrow where neurological disorders no longer limit human potential—to help preserve what makes people who they are.

Our Commitment

Conditions of the nervous system are some of the most complex to understand and treat—posing some of the most difficult scientific challenges of our time. We are up for those challenges.


Genentech is committed to supporting people affected by neurological disorders. As a member of the Roche Group, we have the technology and scientific insights to discover and develop breakthrough medicines for the most common and rare neurological conditions so that we can slow, or even one day reverse, the progression of disease.


But our commitment goes beyond our medicines. Our teams have also been supporting new research through grants, partnering with communities to uncover and test new clinical endpoints, and identifying new digital technologies to diagnose and monitor disease progression.


With our partners across advocacy, academia and industry, we will continue to push the boundaries of scientific understanding to achieve clinical advancements. Together, we hope to solve some of the greatest challenges that have eluded the neuroscience community for generations.

Our Pipeline

For decades, Roche and Genentech have been conducting neuroscience research and clinical trials aimed at exploring areas of the highest medical need. We have grown and advanced our neuroscience portfolio to be one of the most diverse and promising in the industry.


115+ Clinical trials globally in neurological disorders

10+ Investigational medicines in development for rare and common neurological disorders


Our Heritage

Our Perspectives

Learn more about the complexity of neurological disorders and how we’re working to better understand them.

Preserving What Makes Us Who We Are

Our hope is that through our work in neuroscience, we can help preserve the unique qualities that make people who they are.

Read More
The Space Between

A cellular process designed to shape the childhood brain may be reactivated in Alzheimer’s disease.

Read More
Life Planning with MS

Angie, Eliz and Victoria share about life with MS in their 30s and how they are proactive with their health.

Read More

Our News and Publications

Read the latest news and publications about our work in neuroscience.

Molecular Cell, March 2020
Dynamic Regulation of Mitochondrial Import by the Ubiquitin System
Cell Reports, January 2020
GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer’s Disease Models
Journal of Neuroscience, January 2020
Genome-wide Analysis of Differential Gene Expression and Splicing in Excitatory Neurons and Interneuron Subtypes
Cell Reports, December 2019
PPEF2 Opposes PINK1-Mediated Mitochondrial Quality Control by Dephosphorylating Ubiquitin
Cell Reports, August 2019
Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy
Journal of Neuroscience, June 2019
PTCD1 Is Required for Mitochondrial Oxidative-Phosphorylation: Possible Genetic Association with Alzheimer's Disease